Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma

Human Gene Therapy

Volumn 18, Issue 1, 2007, Pages 63-73

  Kanai, Ryuichi ^a   Tomita, Hideyuki ^a   Hirose, Yuichi ^a   Ohba, Shigeo ^a   Goldman, Steven ^b   Okano, Hideyuki ^a   Kawase, Takeshi ^a   Yazaki, Takahito ^a  

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G 207; HERPESVIRUS VECTOR; INFECTED CELL PROTEIN 34.5; INFECTED CELL PROTEIN 8; MUSASHI1 PROTEIN; ONCOLYTIC HERPES VIRUS; RIBONUCLEOTIDE REDUCTASE; RNA BINDING PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; VIRULENCE FACTOR; VIRUS VECTOR KEM34.5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE CONTROL; GENE MUTATION; GLIOBLASTOMA; HERPES SIMPLEX VIRUS 1; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VIVO GENE TRANSFER; MOUSE; MUSASHI1 GENE; NONHUMAN; PROMOTER REGION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TUMOR CELL LINE; VIRAL GENE THERAPY; VIRAL GENETICS; VIRUS EXPRESSION; VIRUS MUTANT; VIRUS RECOMBINATION; VIRUS STRAIN;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENETIC VECTORS; GLIOMA; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NERVE TISSUE PROTEINS; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS (GENETICS); RNA-BINDING PROTEINS; TRANSDUCTION, GENETIC; VIRAL PROTEINS;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1;

EID: 33846235518     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.107     Document Type: Article

References (35)

1. ADVANI, S.J., WEICHSELBAUM, R.R., WHITLEY, R.J., and ROIZMAN, B. (2002). Friendly fire: Redirecting herpes simplex virus-1 for therapeutic applications. Clin. Microbiol. Infect. 8, 551-563.
2. CHIOCCA, E.A. (2002). Oncolytic viruses. Nat. Rev. Cancer 2, 938-950.
3. 134.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shut-off of protein synthesis characteristic of programmed cell death in neuronal cells. Proc. Natl. Acad. Sci. U.S.A. 89, 3266-3270.
4. 134.5, a gene nonessential for growth in culture. Science 250, 1262-1266.
5. CHUNG, R.Y., SAEKI, Y., and CHIOCCA, E.A. (1999). B-myb promoter retargeting of herpes simplex virus γ34.5 gene-mediated virulence toward tumor and cycling cells. J. Virol. 73, 7556-7564.
6. DAVIS, F.G.., FREELS, S., GRUTSCH, J., BARLAS, S., and BREM, S. (1998). Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J. Neurosurg. 88, 1-10.
7. HIROSE, Y., BERGER, M.S., and PIEPER, R.O. (2001). p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 61, 1957-1963.
8. KAMBARA, H., OKANO, H., CHIOCCA, E.A., and SAEKI, Y. (2005). An oncolytic HSV-1 mutant expressing ICP34.5 under control of a Nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 65, 2832-2839.
9. KANAI, R., TOMITA, H., SHINODA, A., TAKAHASHI, M., GOLDMAN, S., OKANO, H., KAWASE, T., and YAZAKI, T. (2006). Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of γ34.5-mediated virulence. Gene Ther. 13, 106-116.
10. KANEKO, Y., SAKAKIBARA, S., IMAI, T., SUZUKI, A., NAKAMURA, Y., SAWAMOTO, K., OGAWA, Y., TOYAMA, Y., MIYATA, T., and OKANO, H. (2000). Musashi1: An evolutionally conserved marker for CNS progenitor cells including neural stem cells. Dev. Neurosci. 22, 139-153.
11. KANEMURA, Y., MORI, K., SAKAKIBARA, S., FUJIKAWA, H., HAYASHI, H., NAKANO, A., MATSUMOTO, T., TAMURA, K., IMAI, T., OHNISHI, T., FUSHIKI, S., NAKAMURA, Y., YAMASAKI, M., OKANO, H., and ARITA, N. (2001). Musashi1, an evolutionarily conserved neural RNA-binding protein, is a versatile marker of human glioma cells in determining their cellular origin, malignancy, and proliferative activity. Differentiation 68, 141-152.
12. KASUYA, H., PAWLIK, T.M., MULLEN, J.T., DONAHUE, J.M., NAKAMURA, H., CHANDRASEKHAR, S., KAWASAKI, H., CHOI, E., and TANABE, K.K. (2004). Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res. 64, 2561-2567.
13. KEYOUNG, H.M., ROY, N.S., BENRAISS, A., LOUISSAINT, A. JR., SUZUKI, A., HASHIMOTO, M., RASHBAUM, W.K., OKANO, H., and GOLDMAN, S.A. (2001). High-yield selection and extraction of two promoter-defined phenotypes of neural stem cells from the fetal human brain. Nat. Biotechnol. 19, 843-850.
14. KHURI, F.R., NEMUNAITIS, J., GANLY, I., ARSENEAU, J., TANNOCK, I.F., ROMEL, L., GORE, M., IRONSIDE, J., MACDOUGALL, R.H., HEISE, C., RANDLEV, B., GILLENWATER, A.M., BRUSO, P., KAYE, S.B., HONG, W.K., and KIRN, D.H. (2000). A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885.
15. KIRN, D. (2001). Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther. 8, 89-98.
16. KIRN, D., MARTIZA, R.L., and ZWIEBEL, J. (2001). Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. 7, 781-787.
17. KRAMM, C.M., CHASE, M., HERRLINGER, U., JACOBS, A., PECHAN, P.A., RAINOV, N.G., SENA-ESTEVES, M., AGHI, M., BARNETT, F.H., CHIOCCA, E.A., and BREAKEFIELD, X.O. (1997). Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8, 2057-2068.
18. MARKERT, J.M., MEDLOCK, M.D., RABKIN, S.D., GILLESPIE, G.Y., TODO, T., HUNTER, W.D., PALMER, C.A., FEIGENBAUM, F., TORNATORE, C., TUFARO, F., and MARTUZA, R.L. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther. 7, 867-874.
19. MARTUZA, R.L., MALICK, A., MARKERT, J.M., RUFFNER, K.L., and COEN, D.M. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856.
20. MINETA, T., RABKIN, S.D., YAZAKI, T., HUNTER, W.D., and MARTUZA, R.L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1, 938-943.
21. MIYATAKE, S.-I., TANI, S., FEIGENBAUM, F., SUNDARESAN, P., TODA, H., NARUMI, O., KIKUCHI, H., HASHIMOTO, N., HANGAI, M., MARTUZA, R.L., and RABKIN, S.D. (1999). Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther. 6, 564-572.
22. MULLEN, J.T., KASUYA, H., YOON, S.S., CARROLL, N.M., PAWLIK, T.M., CHANDRASEKHAR, S., NAKAMURA, H., DONAHUE, J.M., and TANABE, K.K. (2002). Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann. Surg. 236, 502-512.
23. 134.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J. Clin. Invest. 109, 871-882.
24. NIRANJAN, A., WOLFE, D., TAMURA, M., SOARES, M.K., KRISKY, D.M., LUNSFORD, L.D., LI, S., FELLOWS-MAYLE, W., DELUCA, N.A., COHEN, J.B., and GLORIOSO, J.C. (2003). Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Mol. Ther. 8, 530-542.
25. OKANO, H., IMAI, T., and OKABE, M. (2002). Musashi: A translational regulator of cell fates. J. Cell Sci. 115, 1355-1359.
26. OKANO, H., KAWAHARA, H., TORIYA, M., NAKAO, K., SHIBATA, S., and IMAI, T. (2005). Function of RNA binding protein Musashi-1 in stem cells. Exp. Cell Res. 306, 349-356.
27. SAKAKIBARA, S., IMAI, S., HAMAGUCHI, K., OKABE, M., ARUGA, J., NAKAJIMA, K., YASUTOMI, D., NAGATA, T., KURIHARA, Y., UESUGI, S., MIYATA, T., OGAWA, M., MIKOSHIBA, K., and OKANO, H. (1996). Mouse-Musashi-1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell. Dev. Biol. 176, 230-242.
28. SUNDARESAN, P., HUNTER, W.D., MARTUZA, R.L., and RABKIN, S.D. (2000). Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation in mice. J. Virol. 74, 3832-3841.
29. TODA, M., IIZUKA, Y., YU, W., IMAI, T., IKEDA, E., YOSHIDA, K., KAWASE, T., KAWAKAMI, Y., OKANO, H., and UYEMURA, K. (2001). Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia 34, 1-7.
30. TODO, T., FEIGENBAUM, F., RABKIN, S.D., LAKEMAN, F., NEWSOME, J.T., JOHNSON, P.A., MITCHELL, E., BELLIVEAU, D., OSTROVE, J.M., and MARTUZA, R.L. (2000). Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracranial inoculation in Aortus. Mol. Ther. 2, 588-595.
31. TODO, T., MARTUZA, R.L., RABKIN, S.D., and JOHNSON, P.A. (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. U.S.A. 98, 6396-6401.
32. L41 genes of herpes simplex virus 1. J. Virol. 76, 6974-6986.
33. VARGHESE, S., and RABKIN, S.D. (2002). Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 9, 967-978.
34. WAKIMOTO, H., FULCI, G., TYMINSKI, E., and CHIOCCA, E.A. (2004). Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther. 11, 214-223.
35. YAZAKI, T., MANZ, H.J., RABKIN, S.D., and MARTUZA, R.L. (1995). Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 1, 4752-4756.